What Waters's Quarter ended Oct 3, 2026 10-Q says: 4 signals
Waters filed its latest 10-Q with the SEC on Nov 10, 2026. It discusses capex increase, international growth and restructuring charge.
Public (WAT)Biotechnology Research10,000+ employeeswaters.comLinkedIn
Get Waters' live signals in Claude or ChatGPT, or by API
What changed at Waters this week? Use Autobound signals for waters.com.- Filed
- Nov 10, 2026
- Period
- Quarter ended Oct 3, 2026
- Filings
- 3
- Signals
- 16
Source: Autobound Signal API · 72 signals tracked for Waters · updated
10-Q · latest 10
What Waters's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Oct 3, 2026
Filed · 4 signals
Waters Corporation spends $108 million to date implementing a new worldwide ERP system
Waters Corporation anticipates spending approximately $130 million on its worldwide enterprise resource planning system implementation, with $108 million spent through Q3 2026.
$130M
anticipated spending on worldwide ERP implementation
ERP
Waters legacy revenue grew 15% in Asia and 1% in Europe in Q3 2026
Excluding the BDS Business, legacy Waters revenue increased 15% in Asia, 10% in the Americas, and 1% in Europe for the third quarter of 2026 compared to prior year.
15%
legacy revenue increase in Asia for the third quarter of 2026
Waters Corporation incurred $12 million in Q3 2026 workforce reduction severance costs
The company incurred approximately $12 million and $64 million of severance-related costs for the third quarter and first nine months of 2026, respectively, following a 3% workforce reduction implemented in Q2 2026.
$12M
severance-related restructuring costs incurred in the third quarter of 2026
-3%
workforce reduction percentage
Nine-month capital expenditures increased to $150 million from $74 million
Capital expenditures relating to property, plant, equipment and software capitalization totaled $150 million in the first nine months of 2026, up from $74 million in the prior-year period.
$150M
capital expenditures related to property, plant, equipment and software capitalization in first nine months of 2026
- SEC EDGAR
10-Q · Quarter ended Jul 4, 2026
Filed · 6 signals
Waters closed the acquisition of the Biosciences and Diagnostic Solutions business of Becton, Dickinson and Company via a Reverse Morris Trust transaction.
Waters subsidiary Augusta SpinCo borrows $4.0B term loans and issues $3.5B senior notes
Augusta SpinCo borrowed $4.0 billion in unsecured term loans under an agreement with Barclays Bank PLC and later issued $3.5 billion in Senior Notes to repay delayed draw debt.
$3.5B
aggregate principal amount of Senior Notes issued to repay delayed draw term loans
Barclays Bank PLC
Waters Corporation incurs $18 million in first half 2026 for new ERP system implementation
The company incurred $9 million in Q2 and $18 million in the first half of 2026 in expenses associated with its new ERP system implementation.
$18M
expenses associated with new ERP system implementation in first half 2026
ERP
Waters reorganized its operations into Analytical Sciences, Materials Sciences, Biosciences, and Advanced Diagnostics segments following the BDS Business Acquisition.
Revenue in Asia increased 69% to $450 million (with China growing 76% to $206 million) and Europe grew 124% to $505 million in Q2 2026.
69%
revenue growth in Asia in Q2 2026
Waters targets $120 million annual salary savings via workforce reduction initiative
Waters has executed workforce reductions targeting $120 million in annual salary-related cost savings, having achieved $14 million through Q2 2026.
$120M
annual salary-related cost savings from workforce reduction
Earlier 10-Q filings
- 10-Q · Quarter ended Apr 4, 2026Filed · 6 signalsSEC EDGAR
Showing 10 of 16 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Waters earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Q3 revenue reached $1.767B, organic growth up 10%Reported total revenue reached $1.767B with 10% organic constant currency growth, while adjusted operating margin hit 30.1%. Revenue comprised $871M of organic revenue and $896M from Biosciences and Diagnostic Solutions, with geographic revenue reported at $749M in Americas, $523M in Europe, and $495M in Asia. | |
| Full-year revenue guidance raised by $43M to $6.488BFull-year 2026 reported revenue guidance was increased by $43M at the midpoint to $6.479B-$6.497B, driven by stronger organic and acquired performance. Organic constant currency growth guidance was raised by 140 basis points to 9.1%-9.7%, alongside an EPS guidance raise to $14.60-$14.70. | |
| Acquisition of MOBILion Systems to enter discovery proteomicsThe acquisition of MOBILion Systems provides proprietary SLIM high-resolution ion mobility separation technology to combine with mass spectrometry. This entry targets the $2.2B discovery proteomics market, positioning the business for research-grade applications and future routine clinical diagnostics. | |
| Internal AI deployment delivers $200M run-rate cost savingsThe enterprise is leveraging proprietary AI tools for organizational restructuring, spend negotiation, and field service support, completing run-rate cost targets more than two years early. Key deployments include procurement data cube negotiation advisers and a Service AI Advisor that reduced field service visits and lifted first-time fix rates by 10%. | |
| Commercial rollout of AI Link supporting Anthropic protocolsThe company launched Waters AI Link to integrate lab instruments with Anthropic's model context protocol and hardware standards, cutting setup times for autonomous lab workflows from weeks to hours. Additionally, AI-powered peak integration was released for the Empower platform, reducing manual user interventions by up to 95%. | |
| Organic clinical mass spec diagnostic business grew 18%The clinical mass spec business within the Advanced Diagnostics division generated $75M in revenue, expanding 18% in constant currency. Demand expanded double digits across all regions due to LC-MS diagnostic test menu expansion and lead sharing from the acquired Molecular Diagnostics business. |
Signal API · MCP
Track Waters with the Signal API
One POST /v1/companies/enrich call with waters.com returns Waters 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"waters.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Waters 10-Q
When did Waters file its latest 10-Q?
What did Waters disclose in its latest 10-Q?
What did Waters say on its recent earnings calls?
Where can I read Waters's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .